Repair Biotechnologies is developing therapeutics that target cholesterol and aging-related diseases. As human cells cannot break down cholesterol, abnormal accumulation can occur in locations throughout the body and brain contributing to atherosclerosis and metabolic dysfunction. Using their cholesterol degrading platform, Repair is addressing this problem by providing targeted cells with the ability to safely degrade only the unwanted excess cholesterol. This works by delivering an adeno-associated gene therapy vector, which showed in mouse studies to reduce atherosclerotic plaque lipids by 48%. With these promising results, Repair hopes to soon progress to clinical studies.

Repair Biotechnologies

Short description:

Drug notes:

Long description:

Jobs: